Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial - Atreya, R; Peyrin-Biroulet, L; Klymenko, A (Lancet Gastroenterol Hepatol, 2020)
et al.